StockNews.com Initiates Coverage on InVivo Therapeutics (NAS

StockNews.com initiated coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock. Shares of NASDAQ NVIV opened at $4.89 on Monday. The stock has a market cap of $6.80 million, a PE ratio of -0.64 and […]

Related Keywords

, Morgan Stanley , Sigma Securities , Goldman Sachs Group Inc , Virtu Financial , Invivo Therapeutics Holdings Corp , Renaissance Technologies , Invivo Therapeutics , Get Rating , Vivo Therapeutics , Goldman Sachs Group , Vivo Therapeutics Holdings Corp , Neuro Spinal Scaffold , Nasdaq Nviv , Enviv , Medical , Initiated Coverage , Stocknews Com ,